Anti-PD-1 or anti-CTLA-4 in first line therapy?

Long response and long responders in melanoma immunology

Benefit and risk analysis from the phase III OPTiM trial

Progress in targeted therapy of melanoma

Metastatic melanoma: Patient-reported outcomes from the KEYNOTE-002 study

Management of acute metastatic melanoma

How should we handle talimogene laherparepvec (T-VEC)?

Combining immunotherapy with stereotactic body radiotherapy

Systemic immunotherapy and radiotherapy combination shows promise in advanced skin cancer

Is 3D-conformational or intensity-modulated radiation therapy better for NSCLC?

Can early stage NSCLC be treated with stereotactic radiation therapy?

Can SBRT be of use for early, operable non-small cell lung cancer?